Background
Phase III open-label multicenter RCT. N=480 patients with locoregionally advanced NPC, stage III–IVB (excluding T3–T4N0), aged 18–59 years without severe comorbidities, enrolled at 10 Chinese institutions 2011–2013. Tested whether TPF induction chemotherapy added to standard concurrent CRT (cisplatin + IMRT) improves failure-free survival vs CRT alone. All patients received IMRT to 68–70 Gy with concurrent cisplatin 100 mg/m² q3wk × 3 cycles.
Interventions and follow up
Arm A: Induction TPF (docetaxel 60 mg/m² D1 + cisplatin 60 mg/m² D1 + fluorouracil 600 mg/m²/day D1–5 q3wk × 3 cycles) → concurrent cisplatin + IMRT (68–70 Gy)
Arm B: Concurrent cisplatin (100 mg/m² q3wk × 3) + IMRT alone
Primary endpoint: Failure-free survival (FFS)
mFollow up: 45 month
Arm B: Concurrent cisplatin (100 mg/m² q3wk × 3) + IMRT alone
Primary endpoint: Failure-free survival (FFS)
mFollow up: 45 month
Results
3-year FFS: 80% (IC+CRT) vs 72% (CRT alone), HR 0.68 (95% CI 0.48–0.97), P=.034
3-year OS: 92% vs 86%; HR 0.60 (95% CI 0.32–1.13), P=.11 — not significant
Distant failure rate: 8% (IC+CRT) vs 17% (CRT alone)
3-year OS: 92% vs 86%; HR 0.60 (95% CI 0.32–1.13), P=.11 — not significant
Distant failure rate: 8% (IC+CRT) vs 17% (CRT alone)
Adverse events
Main adverse events: Induction phase grade 3–4: neutropenia 42% vs 7% (CRT), leukopenia 41% vs 17%, stomatitis 41% vs 35% (similar in CRT phases). Relative dose intensity for concurrent cisplatin was lower in IC arm (compliance challenge).
Conclusions
TPF induction chemotherapy followed by concurrent CRT significantly improved 3-year failure-free survival (80% vs 72%, HR 0.68) compared to CRT alone in locoregionally advanced NPC. Distant failure rates were halved (8% vs 17%). OS trended in favor of IC but did not reach significance at the 3-year analysis. Induction TPF is now considered a standard option in high-risk LA NPC.
Key Limitations
Key Limitations: OS improvement was not statistically significant at the interim analysis (P=.11) — final OS data needed. Induction TPF substantially increases hematologic toxicity and reduces concurrent cisplatin compliance. Trial enrolled only Chinese patients aged 18–59 — generalizability to older or non-Asian populations is uncertain. Multiple chemotherapy induction regimens are now under study (GP: gemcitabine-cisplatin showed superiority in the SYMPHONY/Sun 2022 JAMA update), superseding the TPF induction standard.
Clinical Context
Sun 2016 Lancet Oncol was pivotal in establishing induction chemotherapy + CRT as the standard approach for high-risk (N2–N3, bulky disease) LA NPC. A 2022 update from the same group (Sun et al, JAMA) and the DIPPER trial demonstrated that induction with GP (gemcitabine + cisplatin) outperforms TPF in NPC, with better tolerability. Current NCCN and ESMO guidelines recommend induction GP → concurrent CRT or concurrent CRT → adjuvant GP for high-risk LA NPC.
References